장마감
로그인 회원가입
PROK
PROK
ProKidney Corp
7월 27일 4:00 PM ET (한국 7/28 05:00)
$1.54
+0.04 ▲ +2.67%
🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)
$1.52
-0.02 ▼ -1.30%

프로키드니(PROK) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$465M
스몰캡
P/E
-
배당수익률
없음
52주 위치
4%
저점 +6% · 고점 -57%
애널리스트
매수
C+
Fundamental health
vs. 성장주 소형주· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 70%
밸류에이션
데이터 부족
재무 안정
Top 33%
Index RUTP/E -EPS (ttm) -0.53Insider Own 72.57%Shs Outstand 142.0MPerf Week -1.28%
Market Cap 0.47BForward P/E -EPS next Y -2.89%Insider Trans -Shs Float 56.3MPerf Month -9.41%
Enterprise Value 1.53BPEG -EPS next Q -0.14Inst Own 24.3%Short Float 37.15%Perf Quarter -20.62%
Income -0.07BP/S 522.67EPS this Y -23.95%Inst Trans 0.48%Short Ratio 18.43Perf Half Y -29.03%
Sales 0.00BP/B -EPS next 5Y 10.52%ROA -20.69%Short Interest 20.91MPerf YTD -31.25%
Book/sh -7.21P/C 2.07EPS past 3/5Y 33.55% 12.93%ROE -52W High -56.62% ($3.55)Perf Year -53.19%
Cash/sh 0.74P/FCF -Sales past 3/5Y -ROIC -52W Low 6.21% ($1.45)Perf 3Y -86.44%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 12.6%Gross Margin -549.38%Volatility(W/M) 5.72% 8.11%Perf 5Y -84.37%
Dividend TTM -EV/Sales 1720.12Sales Y/Y TTM 190.52%Oper. Margin -18959.73%ATR (14) 0.12Perf 10Y -
Dividend Ex-Date -Quick Ratio 9.06EPS Q/Q -8.87%Profit Margin -8131.5%RSI (14) 39.84Recom 2
Dividend Gr. 3/5Y -Current Ratio 9.06Sales Q/Q -1.74%SMA20 -10.53% ($1.72)Beta 1.73Target Price $6.25
Payout -Debt/Eq -Earnings 2026/5/15SMA50 -11.11% ($1.73)Rel Volume 1.1Prev Close $1.5
Employees 231LT Debt/Eq -EPS/Sales Surpr. -1.45% 125.32%SMA200 -27.99% ($2.14)Avg Volume(3M) 1.13MPrice $1.54
IPO 2021/6/30Option/Short Yes/YesTrades 3759Volume 1,242,797Change 2.67%
Quarterly earnings trend SEC filings · USD
23.9
24.3
24.6
24.9
25.3
25.6
25.9
26.3
Revenue Net income 최근 분기: 매출 - · 순이익 $-20M (YoY -20%)

📊 ProKidney Corp (PROK) Investment Analysis

What kind of company is ProKidney Corp?

프로키드니(PROK) 성장주
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

🧬 This is a US-based clinical-stage biotech company developing autologous cell therapies to treat chronic kidney disease. The company is currently running a Phase 3 clinical trial of its innovative therapy, rilparencel, which uses the patient's own kidney cells to restore organ function and delay the need for dialysis. It is leading the way in innovative regenerative medicine technology for kidney disease and offering a new treatment alternative.

Learn more about ProKidney Corp →
Market Cap
$0.5B
Approx. KRW 0.6 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank3265
Employees231people
IPO2021/06/30
Current Price$1.54 ≈ 2,110원
📌 RUT · NASD · USA

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 15일 (금) · 장 시작 전 EPS -1.4% 매출 +125.3%
🔔 Earnings release 2026년 3월 18일 (수) · 장 마감 후 EPS +4.5% 매출 +37066.7%

Is it profitable?

Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-18959.7%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Net Margin
Share of revenue left after taxes and interest are paid
-8131.5%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
-549.4%
✓ 매우 부진
My positionBottom 5%
Low range Average High range
Biotechnology 소형주 Median 84.9% · Bottom tier
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROA
Annual earnings relative to total company assets
-20.7%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Current Ratio
Liquid assets available to cover liabilities due within a year
9.06
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
9.06
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$6.25
현재가 대비 +305.8%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
내년 EPS 예상 성장률
-2.9%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+10.5%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance
Mixed beats and misses
1
예상 상회
0
예상 부합
1
예상 하회
50%
상회 비율
+2.8%
평균 서프라이즈
2026.05.15
하회
실적 $-0.14 · 예상 $-0.14 -1.8%
2026.03.18
상회
실적 $-0.14 · 예상 $-0.15 +7.3%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Expected to Slow
Historical growth is expected to lose momentum
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
-23.9%
매우 부진
My positionBottom 5%
Low range Average High range
성장주 소형주 Median 16.2% · Bottom tier
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
-2.9%
매우 부진
My positionBottom 5%
Low range Average High range
성장주 소형주 Median 17.5% · Bottom tier
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+10.5%
부진
My positionBottom 25%
Low range Average High range
성장주 소형주 Median 18.9% · Bottom 11%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+33.5%
우수
My positionTop 25%
Low range Average High range
성장주 소형주 Median 8.7% · Top 23%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+12.9%
양호
My positionMid-range
Low range Average High range
성장주 소형주 Median 2.9% · Top 34%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
-1.7%
부진
My positionBottom 25%
Low range Average High range
성장주 소형주 Median 7.0% · Bottom 24%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -153%p below the market
PROK -84.4% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-152.7%p
Significantly behind the market
vs Health Care (XLV)
-108.9%p
Significantly behind the sector average
1-year basis
vs S&P 500
-69.2%p
Significantly behind the market
vs Health Care (XLV)
-72.9%p
Significantly behind the sector average
Rank among peers
5-year return Bottom 21% Based on 123 peers
1-year return Lowest among peers Based on 154 peers
Current position within 52-week range
Low (-6.2%p) High (-56.6%p)
Current price is 6.2% above the 52-week low and 56.6% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-38.7%
Annualized volatility
68.7%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $1.54 below the midline ($1.72). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴
Current diagnosis · 2026-07-27
Bearish momentum holding

MACD -0.073 < Signal -0.053 in negative zone + Hist negative (-0.020). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 39.2 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 17.6.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry
Pricey on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🧾 Vs. Sales Pricey
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
522.67x
✓ Very pricey
My positionBottom 5%
Low range Average High range
Biotechnology 소형주 median 14.61x · Bottom 1% — expensive within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
Analyst target price (reference)
$6.25 vs. current price +305.8%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 소형주

Who owns it?

Ownership flow shows some pressure
Institutional modest net buying +0.5% · Short interest very high 37.1% · Short interest up +22.1pp over last 90d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
+0.5%
Institutions net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 24.3%
Moderate institutional participation
Healthcare 소형주 Median 65.6%
🧑‍💼 Insiders 72.6%
Founder/management large holders (strong skin-in-the-game)
Healthcare 소형주 Median 17.6%
👤 Retail investors (estimated) 3.1%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
37.1%
Very high — strong short-side pressure
전체 시장 Median -%
Past 90 days 📈 +22.1%p increase
Short interest days to cover
18.4 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 142.0M주
Float (tradable shares) 56.3M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding PROK

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
PROK PROK This Stock
$465.2M- - - - +2.7%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 프로키드니(PROK)?

프로키드니(PROK) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of PROK?

The market cap of PROK is approximately $465M, ranking 3,265 within its sector.

What is the 52-week high and low for PROK?

PROK has recorded a 52-week high of $3.55 and a low of $1.45.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.